CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向 B7H3 的 CAR-T 细胞在胃癌中的抗肿瘤反应
英文原题：Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells.
查看英文原题
Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的研究表明，B7H3 是 GC 治疗的一个有吸引力的靶点，且 B7H3 具有很高的临床应用潜力。
研究思路结论见上方概要
背景
胃癌（GC）预后差，治疗选择有限。作为一种新的有前景的癌症治疗方法，嵌合抗原受体（CAR）-T细胞代表了潜在的GC治疗手段。我们研究了靶向B7H3的CAR-T 细胞在GC中的抗肿瘤活性。
方法
在我们的研究中，检测了B7H3在GC组织中的表达，并探索了靶向B7H3的CAR-T 细胞在GC中的杀肿瘤潜力。构建了具有人源化抗原识别结构域的B7H3导向CAR-T 细胞。最终在体外和体内研究了该CAR-T 细胞的抗肿瘤效果。
结果
我们的结果表明，B7H3靶向的CAR-T 细胞有效杀伤了GC肿瘤细胞。此外，我们发现B7H3与肿瘤细胞干性相关，抗B7H3 CAR-T 可以同时靶向干细胞样GC细胞以改善治疗结果。
展开英文摘要原文
BACKGROUND
Gastric cancer (GC) has a poor prognosis and limited therapeutic options. As a new promising cancer therapeutic approach, chimeric antigen receptor (CAR)-T cells represent a potential GC treatment. We investigated the antitumor activity of CAR-T cells target-B7H3 in GC.
METHODS
In our study, expression of B7H3 was examined in GC tissues and explored the tumoricidal potential of B7H3-targeting CAR-T cells in GC. B7H3-directed CAR-T cells with a humanized antigen-recognizing domain was generated. The anti-tumor effects of this CAR-T cell were finally investigated in vitro and in vivo.
RESULTS
Our results show that B7H3-directed CAR-T cells efficiently killed GC tumor cells. In addition, we found that B7H3 is correlated with tumor cell stemness, and anti-B7H3 CAR-T can simultaneously target stem cell-like GC cells to improve the treatment outcome.
CONCLUSIONS
Our study indicates that B7H3 is an attractive target for GC therapy, and B7H3 has high potential for clinical application.
论文信息
- 作者
- Sun F、Yu X、Ju R、Wang Z、Wang Y
- 第一作者单位
- Department of Clinical Laboratory, Weifang People's Hospital, Weifang, 261000, Shandong, China.China
- 通讯作者单位
- Department of Clinical Laboratory, Weifang People's Hospital, Weifang, 261000, Shandong, China. Wangyuhui_wfrm@163.com.China
- 期刊
- Cancer cell international2022 Jan 31
- 原文标识
- PubMed 35101032 · DOI 10.1186/s12935-022-02471-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →